School of Medicine
Showing 10,051-10,060 of 13,070 Results
-
Nazish Sayed MD, PhD
Associate Professor (Research) of Surgery (Vascular Surgery)
Current Research and Scholarly InterestsThe Sayed Laboratory investigates how endothelial dysfunction contributes to cardiovascular disease and leverages human stem cell technologies to identify novel therapeutic strategies. Our research integrates patient-derived induced pluripotent stem cells (iPSCs), engineered cardiac tissues, organoids, human biospecimens, and multi-omic technologies to uncover mechanisms underlying inherited and acquired cardiovascular diseases.
A major focus of the laboratory is understanding endothelial–cardiomyocyte communication in cardiomyopathy. Using patient-specific iPSCs, human cardiac organoids, engineered heart tissues, spatial transcriptomics, and single-cell multi-omics, we study how endothelial dysfunction drives myocardial fibrosis, inflammation, and heart failure. Current efforts include investigations into LMNA-related dilated cardiomyopathy, endothelial-to-mesenchymal transition (EndoMT), and mechanisms of fibrotic remodeling.
A second major area of research is cardio-oncology. The laboratory develops human disease models to understand cardiovascular complications associated with cancer therapies, including tyrosine kinase inhibitors and immune checkpoint inhibitors. These studies have identified novel vascular mechanisms underlying treatment-related hypertension, cardiomyopathy, and heart failure.
The laboratory also investigates cardiovascular aging, toxic environmental exposures, rare vascular diseases, and regenerative medicine. By integrating human tissues, advanced stem cell models, genome engineering, spatial biology, and artificial intelligence–enabled multi-omic analyses, our goal is to develop precision therapeutic strategies that improve cardiovascular health and patient outcomes. -
Michael Scahill
Clinical Assistant Professor, Pediatrics - Neonatology
BioOn a trip to Mozambique while in med school here at Stanford, Dr Scahill saw the power of market interventions to transform healthcare. This led to his current focus on technology, data & AI. A veteran data scientist, his research trawls the oceans of data each patient generates for patterns to predict dangerous outcomes before they happen in Stanford's top level NICU, where he also still serves as a frontline clinician. Outside Stanford, he is the digital lead at Valley Children's hospital and advises health technology startups in Silicon Valley and beyond.
-
John Scandling
Professor of Medicine (Nephrology) at the Stanford University Medical Center, Emeritus
Current Research and Scholarly InterestsTolerance induction in clinical kidney transplantation
-
Blake K. Scanlon, Ph.D.
Adjunct Lecturer, Psych/Public Mental Health & Population Sciences
BioThe overarching aim of Dr. Scanlon’s research is to develop and evaluate low-cost, pragmatic and clinically translatable methods for improving management of neurodegenerative disease and dementia. To that end, the Caregiver Technology Division of the Scanlon Lab aims to enhance patient- and family-centered care through novel, broadly customizable, and highly scalable caregiver interventions. In parallel, the Neurodegenerative Division of the Scanlon Lab focuses on the development and application of cognitive, neuropsychiatric, and biological markers for the initiation and progression of neurodegeneration.
Dr. Scanlon received his bachelor’s degree in Neuroscience and doctorate in Clinical Health Psychology from the University of Miami. After concluding his clinical internship in Geropsychology/Neuropsychology at the VA Palo Alto Health Care System (VAPAHCS), he completed fellowships in Aging and Dementia at Stanford University School of Medicine and VAPAHCS. Dr. Scanlon is currently a VA Career Development Awardee in the Sierra-Pacific Mental Illness Research, Education, and Clinical Center (MIRECC) and Stanford/VA Aging Clinical Research Center where his work focuses on developing and evaluating low-cost, pragmatic and clinically translatable methods for improving management of neurodegenerative disease and dementia. He also serves as Co-Director of the Stanford/VA California Alzheimer's Disease Center, Chair of the VAPAHCS Dementia Committee, and Co-Chair of the Department of Veterans Affairs VISN 21 Dementia Committee.
